Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic ...

Dostarlimab is under clinical development by GSK and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction.

BeiGene has won approval from the US Food and Drug Administration for its PD-1 inhibitor Tevimbra (tislelizumab) in ...

The Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr) in combination with platinum and ...

BeiGene (BGNE) has received U.S. FDA approval for its cancer drug Tevimbra in combination with chemotherapy for certain ...

San Mateo, California Monday, December 30, 2024, 18:00 Hrs [IST] ...

More research is needed to refine treatment strategies and identify predictive biomarkers for patient selection, according to researchers.

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

Tevimbra is under clinical development by BeiGene and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC).

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today annou ...